六月 2026
- Home
- SCA Pharma
六月 2026的SCA Pharma市场份额分析
SCA Pharma’s customers have requested extended Beyond Use Dating (BUD), and we are pleased to help meet their needs by extending BUDs on 69 products to date, while still maintaining our stringent quality controls. We anticipate extending BUDs on most or all of our products. Beyond Use Dating (BUD) on compounded sterile preparations is important…
SCA Pharma(包含公司地区分支机构)
查看更多网站流量和参与度信息- scapharma.com
SCA Pharma收入截至 六月 2026为 75M - 100M
SCA Pharma主要域名产生的收入
3 年中SCA Pharma主要域名的收入
SCA Pharma主要域名的收入
SCA Pharma热门域名的总访问量
了解SCA Pharma市场份额和潜在市场覆盖范围。
过去 3 个月的总访问量
子公司明细
SCA Pharma热门域名的平均访问时长
分析SCA Pharma参与度指标。
过去 3 个月的平均访问时长
子公司明细
SCA Pharma热门域名的平均页面浏览量
了解SCA Pharma如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。
过去 3 个月的平均页面浏览量
子公司明细
想要获取更深入的流量洞见?
过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。
SCA Pharma 的新闻与信号
借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。
新闻SCA Pharma hired Hugh O’Neill as Chief Commercial Officer on Mar 9th '23.SCA Pharma, a nationally recognized leader in the 503B compounding pharmaceuticals outsourcing industry providing quality, service, and value to hospitals nationwide, has announced today the addition of Hugh O’Neill as Chief Commercial Officer.
三月 9, 2023阅读更多
新闻SCA Pharma signed new client Vizient, Inc. on Nov 1st '22.SCA Pharma, a nationally recognized leader in the 503B compounded pharmaceuticals outsourcing industry, providing quality, service, and value to hospitals nationwide, has announced today that Vizient has awarded a multi-year agreement to the company for its full range of 503B ready-to-use products.
十一月 1, 2022阅读更多
新闻SCA Pharma hires Scott Luce as Chief Executive Officer.SCA Pharma, which provides high-quality sterile admixture services to hospitals and health-care facilities nationwide, has named Scott Luce as Chief Executive Officer.
七月 17, 2022阅读更多
查看 SCA Pharma 的所有信号
让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。
